Analyst David Risinger of Leerink Partners maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price target of €120.00.
David Risinger has given his Buy rating due to a combination of factors that highlight Sanofi’s strong potential for growth. One of the primary reasons is the company’s attractive valuation, which is currently at 11.2 times the estimated adjusted diluted earnings per share for 2026. This valuation is considered compelling given the projected earnings growth. Furthermore, Sanofi is expected to experience an accelerating earnings growth with a projected compound annual growth rate of 8% from 2025 to 2030.
Another significant factor contributing to the Buy rating is Sanofi’s robust pipeline, which includes several key assets with substantial sales potential. The management has identified three major assets, each with the potential to exceed €5 billion in peak sales, and five additional candidates with potential sales ranging from €2 to €5 billion. These pipeline developments are expected to act as catalysts for the company’s growth, reinforcing the positive outlook on Sanofi’s stock.